it sure looks that way fur. It's kind of funny because as there seems to be more and more questioning by folks on here about the company being able to meet their short-term promised milestones, yet every rock that's overturned makes ONCS look like more of a potential home run long-term. I would venture to guess that there are many investors who entered ONCS at some point in the last year thinking of it as a one-year type of play as they are finishing up Phase 2 melanoma trials, maybe thinking they had a good chance at a run to $1 - $1.50 and then they could get out. Now we are faced with a situation where that short term $1 - $1.50 seems to be doubted by many but the long term potential could be so much more than many ever imagined.
News 
Market Data 
Discover 
